
Sign up to save your podcasts
Or


Send a text
Welcome back Rounds Table Listeners! As we approach the end of 2023, let’s revisit five important research studies from 2022: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (0:00 – 2:56) Tirzepatide Once Weekly for the Treatment of Obesity (2:56 – 6:00) Empagliflozin in Patients with Chronic Kidney Disease (6:00 – ...
The post TBT – The Top Papers of 2022 appeared first on Healthy Debate.
By Dr. John Fralick and Dr. Michael Fralick5
1212 ratings
Send a text
Welcome back Rounds Table Listeners! As we approach the end of 2023, let’s revisit five important research studies from 2022: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (0:00 – 2:56) Tirzepatide Once Weekly for the Treatment of Obesity (2:56 – 6:00) Empagliflozin in Patients with Chronic Kidney Disease (6:00 – ...
The post TBT – The Top Papers of 2022 appeared first on Healthy Debate.

91,246 Listeners

43,818 Listeners

320 Listeners

542 Listeners

706 Listeners

501 Listeners

3,387 Listeners

1,141 Listeners

67 Listeners

520 Listeners

367 Listeners

258 Listeners

320 Listeners

10,983 Listeners

4,325 Listeners